Literature DB >> 1945322

Treatment of acute Graves orbitopathy.

M Kazim1, S Trokel, S Moore.   

Abstract

The therapeutic options for the treatment of acute Graves orbitopathy include high-dose oral corticosteroids, surgical decompression, and radiotherapy. The former two treatments are associated with significant morbidity. Although there have been a number of reports of the efficacy of radiotherapy, its role in the management of this disease is still questioned. The authors reviewed 84 cases of acute Graves orbitopathy treated with either high-dose systemic corticosteroids or radiotherapy (2000 rad to each involved orbit). Radiotherapy resulted in significant improvement in subjective and objective signs of orbital congestion and was more effective than high-dose corticosteroids in relieving compressive optic neuropathy. Of the patients with compressive optic neuropathy, only 1 of 29 treated with radiotherapy required surgical decompression, whereas, 6 of 16 treated with corticosteroids required surgery. This study suggests that radiotherapy has greater efficacy and fewer complications than high-dose systemic corticosteroids in the treatment of acute Graves orbitopathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1945322     DOI: 10.1016/s0161-6420(91)32114-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  Reversal of dysthyroid optic neuropathy following orbital fat decompression.

Authors:  M Kazim; S L Trokel; G Acaroglu; A Elliott
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Quantification of orbital apex crowding for screening of dysthyroid optic neuropathy using multidetector CT.

Authors:  A C P Gonçalves; L N Silva; E M M S Gebrim; M L R Monteiro
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-22       Impact factor: 3.825

3.  Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

Authors:  K A Ponto; T Diana; H Binder; N Matheis; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

Review 4.  The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Authors:  Yang Wang; Huifang Zhou; Xianqun Fan
Journal:  Front Med       Date:  2017-05-13       Impact factor: 4.592

5.  Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy.

Authors:  Chan Jeon; Jae Ho Shin; Kyung In Woo; Yoon-Duck Kim
Journal:  Korean J Ophthalmol       Date:  2012-03-22

6.  Contour Variability in Thyroid Eye Disease with Compressive Optic Neuropathy Treated with Radiation Therapy.

Authors:  Tavish Nanda; Andrew Sanchez; Juhi Purswani; Cheng-Chia Wu; Michael Kazim; Tony J C Wang
Journal:  Adv Radiat Oncol       Date:  2020-02-29

7.  Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone.

Authors:  R Ebner; M H Devoto; D Weil; M Bordaberry; C Mir; H Martinez; L Bonelli; H Niepomniszcze
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

8.  Using frequency-doubling perimetry to detect optic neuropathy in patients with Graves' orbitopathy.

Authors:  Mário L R Monteiro; André L F Portes; Frederico C Moura; Dina B W Regensteiner
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

9.  Diagnostic ability of Barrett's index to detect dysthyroid optic neuropathy using multidetector computed tomography.

Authors:  Mário L R Monteiro; Allan C P Gonçalves; Carla T M Silva; Janete P Moura; Carolina S Ribeiro; Eloisa M M S Gebrim
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

10.  [Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; G Gusek-Schneider; S Barth; J Hensen; F Wolf; G O Naumann; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-09       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.